Imnovid (Pomalidomide)

Imnovid is an immunomodulatory agent used in the management of multiple myeloma, particularly in patients whose disease has progressed after prior therapies.

• Relapsed multiple myeloma: provides disease control after previous treatment failure.
• Refractory multiple myeloma: offers a therapeutic option when disease does not respond to earlier regimens.
• Patients previously treated with lenalidomide and bortezomib: extends progression‑free survival in this heavily pre‑treated population.

• Pomalidomide binds to the cereblon component of the CRL4 E3 ubiquitin ligase complex, altering substrate specificity. This leads to ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos, resulting in immunomodulation, anti‑angiogenic effects, and direct anti‑myeloma activity through apoptosis and cell‑cycle arrest.

Adverse reactions to Imnovid may vary in frequency and severity.

Common Side Effects

• Fatigue: persistent tiredness reported by many patients.
• Neutropenia: reduced neutrophil count increasing infection risk.
• Anemia: lowered red blood cell levels causing weakness.
• Constipation: decreased bowel movements.
• Diarrhea: loose stools.
• Rash: mild skin eruptions.

Serious or Rare Side Effects

• Thromboembolic events: deep vein thrombosis or pulmonary embolism.
• Severe neutropenia: markedly low neutrophil counts requiring medical intervention.
• Stevens‑Johnson syndrome: severe skin reaction.
• Tumor lysis syndrome: rapid tumor cell breakdown.
• Second primary malignancies: emergence of new cancers.

Before initiating Imnovid, several safety considerations should be observed.

• Pregnancy avoidance: contraindicated in pregnancy (Category X).
• Teratogenic risk: ensure effective contraception for both patient and partner.
• Blood monitoring: perform regular complete blood counts to detect cytopenias.
• Infection risk: monitor for signs of infection and manage promptly.
• Thromboembolism prophylaxis: assess risk factors and consider anticoagulation when appropriate.
• Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Imnovid may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors: may increase pomalidomide exposure.
• Strong CYP3A4 inducers: may reduce pomalidomide exposure.
• Anticoagulants: increased risk of bleeding.
• Live vaccines: contraindicated due to immunosuppression.

Moderate Interactions (Monitor Closely)

• Antihistamines: may enhance sedation.
• NSAIDs: may increase risk of thrombocytopenia.
• CYP3A4 substrates: may require dose adjustment.
• Hormonal contraceptives: efficacy may be reduced, consider alternative methods.